Login to Your Account



Benlysta Blockbuster BLISS?

Street Thrown for a 'Lupus' as HGS Posts Phase III Win

By Randy Osborne


Tuesday, July 21, 2009
Full rejoicing must wait until November, when the second - and somewhat riskier - lupus trial will report data, but Human Genome Sciences Inc. meanwhile has wowed investors with positive top-line results from a Phase III study with Benlysta (belimumab). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription